Dinaciclib (BioDeep_00000651961)
代谢物信息卡片
化学式: C21H28N6O2 (396.2274)
中文名称: Dinaciclib
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO
InChI: InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:95060
- KEGGdrug: D09604
- PubChem: 46926350
- DrugBank: DB12021
- ChEMBL: CHEMBL2103840
- CAS: 779353-01-4
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Yichen Li, Zhenjiang Zheng, Li Xiao, Yonghua Chen, Xubao Liu, Dan Long, Li Chai, Yi Li, Chunlu Tan. Dinaciclib exerts a tumor-suppressing effect via β-catenin/YAP axis in pancreatic ductal adenocarcinoma.
Anti-cancer drugs.
2023 Sep; ?(?):. doi:
10.1097/cad.0000000000001545. [PMID: 37694833] - Luke J Nelson, Kyleen E Castro, Binzhi Xu, Junyi Li, Nguyen B Dinh, Jordan M Thompson, Jordan Woytash, Kevin R Kipp, Olga V Razorenova. Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma.
Cell cycle (Georgetown, Tex.).
2022 05; 21(10):1103-1119. doi:
10.1080/15384101.2022.2041783. [PMID: 35240916] - Peng Zhang, Jason Miska, Catalina Lee-Chang, Aida Rashidi, Wojciech K Panek, Shejuan An, Markella Zannikou, Aurora Lopez-Rosas, Yu Han, Ting Xiao, Katarzyna C Pituch, Deepak Kanojia, Irina V Balyasnikova, Maciej S Lesniak. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
Proceedings of the National Academy of Sciences of the United States of America.
2019 11; 116(47):23714-23723. doi:
10.1073/pnas.1906346116. [PMID: 31712430] - Monica M Mita, Alain C Mita, Jennifer L Moseley, Jennifer Poon, Karen A Small, Ying-Ming Jou, Paul Kirschmeier, Da Zhang, Yali Zhu, Paul Statkevich, Kamelesh K Sankhala, John Sarantopoulos, James M Cleary, Lucian R Chirieac, Scott J Rodig, Rajat Bannerji, Geoffrey I Shapiro. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
British journal of cancer.
2017 Oct; 117(9):1258-1268. doi:
10.1038/bjc.2017.288. [PMID: 28859059] - Esther P Jane, Daniel R Premkumar, Jonathon M Cavaleri, Philip A Sutera, Thatchana Rajasekar, Ian F Pollack. Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.
The Journal of pharmacology and experimental therapeutics.
2016 Feb; 356(2):354-65. doi:
10.1124/jpet.115.230052. [PMID: 26585571] - Daniela Cihalova, Martina Ceckova, Radim Kucera, Jiri Klimes, Frantisek Staud. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
Biochemical pharmacology.
2015 Dec; 98(3):465-72. doi:
10.1016/j.bcp.2015.08.099. [PMID: 26300056]
